A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007)

Summary

Researchers are looking for a new way to treat people with non-segmental vitiligo (NSV). The goal of this study is to learn about the safety of MK-6194 and how well people tolerate it. Researchers also want to learn if people who take MK-6194 have more of a decrease in the amount of vitiligo on their face compared to people who take placebo.

Timeline

Start

2023-11-27

Primary completion

2025-03-20

Completion

2025-07-30

Outcome

Missed primary endpoint

Stopped (Business): “Business Reasons”

registry analysis (superiority test); MK-6194 3 mg Q2W vs Placebo; p = 0.949; NCT06113328 ↗

registry analysis (superiority test); MK-6194 3 mg Q4W vs Placebo; p = 0.343; NCT06113328 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MK-6194	Unknown	3 mg	Subcutaneous

Indications